Can a newer drug outperform an older one in preventing spine fractures for acromegaly?
NCT ID NCT07179926
Summary
This study aims to see if a drug called Pasireotide LAR is better than another drug, Pegvisomant, at preventing spine fractures in adults with acromegaly whose disease is not well-controlled. Acromegaly often weakens bones, making fractures common. Researchers will compare the rate of new spine fractures over one year in 120 patients taking one of these two medications.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACROMEGALY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fondazione Policlinico Universitario Agostino Gemelli IRCCS UOC Endocrinologia e Diabetologia
RECRUITINGRome, RM, 00168, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.